Chemistry:Atinvicitinib
Atinvicitinib is a veterinary medicinal product under investigation for the treatment of atopic dermatitis in dogs.[1] Atinvicitinib is a selective Janus kinase (JAK) inhibitor, highly selective for Janus kinase 1 (JAK1). It inhibits the function of a variety of cytokines involved in itch and inflammation, as well as cytokines involved in allergy, that are dependent on JAK1 enzyme activity.[1] Reduction of allergy mediated inflammation, which is dependent on JAK1 enzyme activity, leads to a reduction of inflammation associated white blood cell counts (within the reference range).[1]
Society and culture
Legal status
In June 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Numelvi, tablets, intended for dogs.[1] The applicant for this veterinary medicinal product is Intervet International B.V.[1]
Names
Atinvicitinib is the international nonproprietary name.[2]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Numelvi EPAR". 11 June 2025. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/numelvi. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information 36 (3). 2022.
 |  |
